摘要
目的与盐酸多奈哌齐对照比较盐酸美金刚治疗阿尔茨海默病(Alzheimer disease,AD)的有效性和安全性。方法将36例AD患者随机分为两组,采用双盲双模拟的方法,对照组给予盐酸多奈哌齐10mg/d,试验组给予盐酸美金刚20mg/d,疗程16周,每4周随访1次,评估简易精神状态量表(MMSE)、阿尔茨海默病评价量表-认知分量表(ADAS-cog)、日常生活能力量表(ADL)、临床疗效总评量表(CGI)、快速词汇测验(RVR)和数字广度测验(DS)。结果32例患者完成了本试验,盐酸多奈哌齐组MMSE、ADAS-cog、ADL、RVR和DS评分治疗前后比较均有统计学意义(P<0.05),盐酸美金刚组ADL、ADAS-cog和MMSE评分治疗前后比较有统计学意义(P<0.05)。治疗前两组各量表评分比较(P>0.05)与治疗16周后两组评分比较(P>0.05),均无统计学差异。结论盐酸美金刚作为治疗AD的新药,可以改善AD患者的症状,疗效与盐酸多奈哌齐相当,且具有良好的安全性和耐受性。
Objective To evaluate the clinical efficacy and safety of akatinol memantine in the treatment of Alzheimer disease （AD）. Methods 36 patients with AD were randomly assigned to receive 10 mg of donepezil daily or 20 mg of memantine daily for 16 weeks. The primary efficacy were evaluated by using the Mini-Mental Status Examination （ MMSE）, the Alzheimer Disease Assessment Stc.ale-cognition （ADAS-cog） and the Activities of Daily Living （ADL）. The secondary efficacy were evaluated by using the Clinical Global Impression （CGI） , the Rapid Verbal Retrieve （RVR） and the Digit Span （DS）. Results 32 patients （50% women; mean age, 66 years） completed the study and were evaluated. Memanfine had similar efficacies to donepezil in improving symptoms of Alzheimer disease as evidenced by the increase in scores of MMSE, RVR as well as DS and the decrease in scores of ADL （ P 〈 0. 05 ）. Conclusions Our current data showed that memantine as a new drug for AD, had the similar efficaces as donepezil.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2008年第1期6-9,共4页
Chinese Journal of Nervous and Mental Diseases
